

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1 (Currently amended). ~~A nona or decapeptide which appears~~ peptide consisting of:

(a) 9 or 10 contiguous amino acid residues that appear in the sequence of Lactadherin (BA-46), which peptide is selected so as to promote promotes effective binding to a MHC class 1 type molecule so as to elicit a CTL response; or

(b) a non-natural modification of (a) to form a modified peptide that promotes effective binding to a MHC class 1 type molecule so as to elicit a CTL response.

Claims 2-15 (Cancelled)

16 (Currently amended). ~~[[The]] A peptide of claim 1 selected from the group consisting of SEQ ID NOs: 35, 36, 37, 38, 39, 40, 41 or and 41.~~

Claims 17-18 (Cancelled)

19 (Previously presented). The peptide of claim 1, wherein said peptide is derived from a mammal.

20 (Previously presented). The peptide of claim 19, wherein the mammal is a human or a rodent.

21(Previously presented). The peptide of claim 1, wherein said peptide includes at least one non-natural modification.

Claim 22 (Cancelled)

23(Previously presented). The peptide of claim 21, wherein said at least one modification is selected from the group consisting of peptoid modification, cyclic peptide modification, N terminus modification, C terminus modification, peptide bond modification, backbone modification and residue modification.

24(Previously presented). A pharmaceutical composition comprising, as an active ingredient, at least one peptide as set forth in claim 1 and a pharmaceutically acceptable carrier.

Claim 25 (Cancelled)

26(Previously presented). The pharmaceutical composition of claim 24, wherein the composition is effective to inhibit cancer or cancer metastases.

27(Original). The pharmaceutical composition of claim 26, wherein said cancer is selected from the group consisting of breast, bladder, prostate, pancreas, ovary, thyroid, colon, stomach and head and neck cancer.

28(Original). The pharmaceutical composition of claim 26, wherein said cancer is a carcinoma.

29(Original). The pharmaceutical composition of claim 24, wherein the composition is a vaccine.

30(Previously presented). A vaccine composition comprising, as an active ingredient, at least one peptide as set forth in claim 1 and a suitable carrier.

31(Previously presented). The vaccine composition of claim 30, wherein said carrier is selected from the group consisting of a proteinaceous carrier to which said at least one peptide is linked, an adjuvant, a protein or a recombinant protein and an antigen presenting cell.

32(Previously presented). The vaccine composition of claim 30, wherein the composition is effective to inhibit cancer or cancer metastases.

33(Original). The vaccine composition of claim 32, wherein said cancer is selected from the group consisting of breast, bladder, prostate, pancreas, ovary, thyroid, colon, stomach and head and neck cancer.

34(Original). The vaccine composition of claim 32, wherein said cancer is a carcinoma.

Claims 35-43 (Cancelled)

44(Original). The peptide of claim 1, wherein the second residue and the end residue are neutral, hydrophobic and aliphatic.

Appln. No. 09/744,804
Amdt. dated September 17, 2003
Reply to Office Action of June 19, 2003

45(Previously presented). The pharmaceutical composition of claim 24 also comprising a peptide having a helper T cell epitope.

Claims 46-52 (Cancelled)

53(Previously presented). The pharmaceutical composition of claim 26, wherein said cancer is breast cancer.

54(Previously presented). The vaccine composition of claim 32, wherein said cancer is breast cancer.

55(Previously presented). The peptide according to claim 16, consisting of SEQ ID NO:38.

56(Previously presented). The peptide according to claim 16, consisting of SEQ ID NO:39.

57(Previously presented). The peptide according to claim 16, consisting of SEQ ID NO:41.

58(New). The peptide of claim 1, consisting of 9 or 10 contiguous amino acid residues that appear in the sequence of Lactadherin (BA-46), which peptide promotes effective binding to a MHC class 1 type molecule so as to elicit a CTL response.